Tobacco / Nicotine Use Disorder

Understanding Nicotine Use Disorder

What It Is

Nicotine use disorder is the persistent, problematic use of nicotine-containing products. Nicotine acts at nicotinic acetylcholine receptors in the brain, producing dopamine release in the reward pathway and rapid tolerance. Because nicotine is delivered to the brain within seconds — particularly via smoked tobacco — the reinforcement schedule is unusually powerful: every puff is a separate reward, dozens to hundreds of times per day.

Why It's So Hard to Quit

• Rapid delivery and short duration produce frequent, intensely reinforcing reward cycles
• Nicotine receptors upregulate with chronic exposure, producing dependence within weeks
• Withdrawal is unpleasant and begins within hours
• Behavior is tightly tied to daily routines and emotional cues
• Nicotine is legal, cheap, and socially embedded for many users
• Many smokers use nicotine to manage other untreated conditions — anxiety, depression, ADHD, weight

Who Develops It

Nicotine use disorder occurs across every demographic, with elevated rates in those with co-occurring psychiatric or substance use disorders, lower socioeconomic status, and certain occupational groups. Smoking rates among people with serious mental illness are several times higher than the general population, contributing significantly to the mortality gap in those communities.

DSM-5 Diagnostic Criteria

Tobacco use disorder requires 2 or more of the following 11 criteria within a 12-month period:

Impaired Control

1. Tobacco taken in larger amounts or over a longer period than intended
2. Persistent desire or unsuccessful efforts to cut down or control use
3. Great deal of time spent obtaining or using tobacco
4. Craving — strong desire or urge to use tobacco

Social Impairment

5. Recurrent use resulting in failure to fulfill major role obligations (e.g., interference with work)
6. Continued use despite persistent social or interpersonal problems caused or worsened by tobacco (e.g., arguments with others about smoking)
7. Important activities given up or reduced because of use

Risky Use

8. Recurrent use in physically hazardous situations (e.g., smoking in bed)
9. Continued use despite knowledge of persistent physical or psychological problems likely caused or worsened by tobacco

Pharmacological

10. Tolerance — markedly increased amounts needed, or diminished effect with the same amount
11. Withdrawal — characteristic withdrawal syndrome, or tobacco used to relieve or avoid withdrawal

Severity

• Mild: 2–3 criteria
• Moderate: 4–5 criteria
• Severe: 6 or more criteria

Modern Nicotine Products

Combustible Tobacco

Cigarettes, cigars, pipes, hookah. Combustion produces thousands of additional toxic compounds beyond nicotine. Combustible tobacco causes the vast majority of tobacco-related mortality.

Smokeless Tobacco

Chewing tobacco, snuff, snus. Lower respiratory risk but elevated oral, esophageal, and pancreatic cancer risk. Nicotine delivery is slower than smoking but produces sustained levels.

Electronic Cigarettes and Vapes

Devices that aerosolize nicotine-containing liquid. Generally believed to be substantially less harmful than combustible tobacco at the individual level for adult smokers who completely switch. Long-term effects remain incompletely studied. Vaping is not "harmless" — concerns include lung injury, cardiovascular effects, and unknowns about chronic use.

Nicotine Pouches

Tobacco-free pouches placed in the mouth (Zyn and similar products). High and rapidly delivered nicotine doses. Marketing has been aggressive; adolescent and young adult uptake has risen sharply.

The Adolescent Vaping Concern

Adolescent vaping has become a major public health concern. Modern devices deliver high-dose nicotine in discreet form. Adolescents who vape have substantially elevated rates of transitioning to combustible tobacco. Nicotine exposure during adolescence interferes with brain development and increases risk of long-term dependence.

Heated Tobacco Products

Products that heat rather than burn tobacco (IQOS and similar). Reduced exposure to some combustion-related toxicants, but not "safe" — and adoption patterns suggest dual use with cigarettes rather than complete switching.

Nicotine Withdrawal

Course

Nicotine withdrawal begins within hours of the last use, peaks in the first 2–3 days, and largely resolves over 2–4 weeks. Cravings can persist for months, particularly in response to specific triggers. Although not life-threatening, nicotine withdrawal is one of the most consistently uncomfortable substance withdrawal syndromes.

DSM-5 Withdrawal Symptoms

Four or more of the following occurring within 24 hours after abrupt cessation or reduction:

• Irritability, frustration, or anger
• Anxiety
• Difficulty concentrating
• Increased appetite
• Restlessness
• Depressed mood
• Insomnia

Cravings

Acute cravings typically last 3–5 minutes. Distraction, urge surfing, water, brief activity, and chewing or biting alternatives all help. With each unanswered craving, the craving response weakens slightly. Over weeks, the frequency and intensity drop substantially.

Weight Gain

Modest weight gain (4–5 kg on average) is common after quitting, due to slowed metabolism and increased appetite. This is not inevitable, can be mitigated, and is a small price for the dramatic health benefits of quitting. Weight gain concerns should not delay quitting.

Health Consequences

Respiratory

• Lung cancer (cigarettes cause approximately 80–90% of lung cancers)
• Chronic obstructive pulmonary disease (COPD)
• Chronic bronchitis
• Increased respiratory infections

Cardiovascular

• Coronary artery disease
• Myocardial infarction
• Stroke
• Peripheral vascular disease
• Aortic aneurysm

Cancer

Beyond lung cancer: oral, pharyngeal, laryngeal, esophageal, pancreatic, kidney, bladder, cervical, colorectal, stomach, and acute myeloid leukemia.

Pregnancy and Reproductive

• Reduced fertility
• Increased miscarriage and stillbirth
• Preterm birth and low birth weight
• Sudden infant death syndrome (SIDS)
• Long-term effects on offspring respiratory and neurodevelopmental outcomes

Other

• Wound healing impairment
• Periodontal disease and tooth loss
• Cataracts and macular degeneration
• Bone density loss
• Premature skin aging

Benefits of Quitting

• 20 minutes: heart rate and blood pressure drop
• 12 hours: blood carbon monoxide normalizes
• 2 weeks–3 months: circulation and lung function improve
• 1 year: heart disease risk drops by half compared to continued smoking
• 5–10 years: stroke risk approaches that of never-smokers
• 10 years: lung cancer death rate falls to about half that of continuing smokers
• 15 years: heart disease risk approaches that of never-smokers

Causes and Risk Factors

Genetic

Heritability of nicotine dependence is approximately 50%. Variants in nicotinic receptor genes and CYP2A6 (which metabolizes nicotine) influence both initial response and dependence patterns.

Age of Initiation

Nearly all lifelong smokers begin in adolescence. Initiation before age 18 is associated with substantially higher rates of lifelong dependence. Adolescent brain reward systems are particularly sensitive to nicotine.

Co-occurring Conditions

• Mental illness — particularly schizophrenia, bipolar disorder, depression, anxiety
• Other substance use disorders, especially alcohol
• ADHD
• PTSD

Social and Environmental

• Parental and peer smoking
• Lower socioeconomic status
• Marketing and product accessibility
• Tobacco-friendly social environments

Assessment

Brief Screening

• Universal screening at every healthcare encounter is the standard of care
• Five A's framework: Ask, Advise, Assess, Assist, Arrange

Assessing Severity

• Fagerström Test for Nicotine Dependence: 6-item measure; widely used
• Time to first cigarette in the morning is one of the most informative single questions
• Number per day; pack-years; prior quit attempts and outcomes

Medical Assessment

Cardiovascular, respiratory, and oral examination. Spirometry when COPD is suspected. Cancer screening per guidelines. Lung cancer screening with low-dose CT is recommended for those meeting age and pack-year criteria.

Evidence-Based Treatment

Treatment combines medication and behavioral support. Combined treatment roughly triples one-year quit rates compared with willpower alone.

Nicotine Replacement Therapy (NRT)

NRT provides nicotine in a form that avoids the rapid spikes of smoking, easing withdrawal while behavior change happens.

• Patch: Long-acting baseline coverage
• Gum, lozenge, inhaler, nasal spray: Short-acting, for breakthrough cravings
• Combination NRT (patch + short-acting) is more effective than either alone
• Available over the counter in many countries

Varenicline (Chantix / Champix)

Partial agonist at the α4β2 nicotinic receptor. Reduces craving and the rewarding effect of smoking. The most effective single medication for smoking cessation. Side effects include nausea and vivid dreams; earlier concerns about neuropsychiatric effects have not been borne out in large trials.

Bupropion (Zyban)

An atypical antidepressant that also reduces craving. Useful particularly when depression coexists. Contraindicated in seizure disorders and current bulimia or anorexia.

Cytisine

A plant-derived nicotinic partial agonist long used in Eastern Europe. Effectiveness comparable to varenicline at much lower cost. Availability in the US has been limited historically but is changing.

Behavioral Interventions

• Brief clinician counseling: Even 3–10 minutes increases quit success
• Quitlines: Free phone-based counseling with strong evidence (1-800-QUIT-NOW in the US)
• Text-based programs: SmokeFreeTXT and similar services
• Mobile apps: Quit STAR and other evidence-supported apps
• Cognitive Behavioral Therapy: Targets cues, beliefs, and coping
• Contingency management: Strong evidence in clinical and pregnant populations

E-Cigarettes as a Cessation Tool

Evidence is mixed but growing. Some randomized trials show e-cigarettes can outperform traditional NRT for cessation. Public health authorities differ in their stance. For an established adult smoker who has failed traditional approaches, complete switching to e-cigarettes is likely less harmful than continued smoking, but it is not the cleanest path. For never-smokers, especially adolescents, vaping is a new exposure to nicotine, not a cessation tool.

Treating Co-occurring Conditions

Treating depression, anxiety, ADHD, and other substance use disorders improves smoking cessation outcomes. Bupropion or varenicline can serve double duty when used appropriately.

A Realistic Approach to Quitting

Set a Quit Date

Choose a date within the next 2 weeks. Tell people you trust. Remove tobacco products and associated items from your environment.

Plan Medication in Advance

Start NRT, varenicline, or bupropion on or before the quit date as prescribed. Varenicline is typically started 1 week before the quit date; bupropion 1–2 weeks before; NRT can be started on the quit date or earlier as a preload.

Identify Triggers

Specific times, places, emotions, and people that prompt smoking. Plan replacements in advance — coffee without a cigarette is a different ritual that needs to be designed, not improvised.

Manage Cravings

• Delay — most cravings pass within minutes
• Deep breathing
• Drink water
• Distract — brief activity, walk, call a friend
• Use short-acting NRT

Plan for Lapses

A single cigarette is not a failure. Identify what happened, what you'll do differently, and resume the plan. Most successful quitters lapse before succeeding.

Treat Each Attempt as a Learning Opportunity

Most lifelong quitters made multiple attempts before sustained success. Each attempt builds knowledge — about triggers, about medications, about the structure of withdrawal — that the next attempt benefits from.

Supporting a Loved One

What Helps

• Ask if and how they want support; do not assume
• Avoid lectures, ultimatums, and surveillance
• Acknowledge the difficulty; nicotine withdrawal is uncomfortable
• Encourage use of evidence-based medications and counseling
• Mark progress — days, weeks, months — and celebrate

What to Avoid

• Treating lapses as moral failure
• Believing willpower is the active ingredient
• Discouraging NRT or varenicline because they "still contain medication"
• Pressure that increases stress during early withdrawal